Free Trial
NASDAQ:ORKA

Oruka Therapeutics Q1 2025 Earnings Report

Oruka Therapeutics logo
$15.00 -0.33 (-2.15%)
Closing price 04:00 PM Eastern
Extended Trading
$14.96 -0.04 (-0.23%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oruka Therapeutics EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Oruka Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oruka Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

Oruka Therapeutics Earnings Headlines

Wedbush Reiterates "Outperform" Rating for Oruka Therapeutics (NASDAQ:ORKA)
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More Oruka Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email.

About Oruka Therapeutics

Oruka Therapeutics (NASDAQ:ORKA) is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

View Oruka Therapeutics Profile

More Earnings Resources from MarketBeat